100 related articles for article (PubMed ID: 20233802)
1. The value of new chemotherapeutic agents for metastatic colorectal cancer.
Howard DH; Kauh J; Lipscomb J
Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer.
van den Hout WB; Kramer GW; Noordijk EM; Leer JW
J Natl Cancer Inst; 2006 Dec; 98(24):1786-94. PubMed ID: 17179480
[TBL] [Abstract][Full Text] [Related]
3. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group.
Van Den Brink M; Van Den Hout WB; Stiggelbout AM; Klein Kranenbarg E; Marijnen CA; Van De Velde CJ; Kievit J;
J Clin Oncol; 2004 Jan; 22(2):244-53. PubMed ID: 14665610
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
6. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.
Woodward RM; Brown ML; Stewart ST; Cronin KA; Cutler DM
Cancer; 2007 Dec; 110(11):2511-8. PubMed ID: 17955504
[TBL] [Abstract][Full Text] [Related]
7. The value of medical spending in the United States, 1960-2000.
Cutler DM; Rosen AB; Vijan S
N Engl J Med; 2006 Aug; 355(9):920-7. PubMed ID: 16943404
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
9. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study.
Etzioni R; Ramsey SD; Berry K; Brown M
Health Econ; 2001 Apr; 10(3):245-56. PubMed ID: 11288190
[TBL] [Abstract][Full Text] [Related]
10. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
13. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of treatment of early stage endometrial cancer.
Ashih H; Gustilo-Ashby T; Myers ER; Andrews J; Clarke-Pearson DL; Berry D; Berchuck A
Gynecol Oncol; 1999 Aug; 74(2):208-16. PubMed ID: 10419733
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers.
Porter GA; Cantor SB; Walsh GL; Rusch VW; Leung DH; DeJesus AY; Pollock RE; Brennan MF; Pisters PW
J Thorac Cardiovasc Surg; 2004 May; 127(5):1366-72. PubMed ID: 15115994
[TBL] [Abstract][Full Text] [Related]
16. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
17. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer.
Ramsey SD; Berry K; Etzioni R
Am J Gastroenterol; 2002 Feb; 97(2):440-5. PubMed ID: 11866285
[TBL] [Abstract][Full Text] [Related]
18. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
19. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
20. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
Hillner BE; McLeod DG; Crawford ED; Bennett CL
Urology; 1995 Apr; 45(4):633-40. PubMed ID: 7716844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
